Celltrion nabs Herceptin biosim nod in S. Korea; Hungary approves Novartis' generic Advair;

@FiercePharma: FDA: The social media guidance puzzle will be complete by July. More | Follow @FiercePharma

@TracyStaton: Hungary joins the club of EU countries approving Novartis' generic version of GSK's blockbuster Advair. News | Follow @TracyStaton

@EricPFierce: FDA investigator assigned to Europol to fight fakes being hawked online by drug rings. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Allergan rides high on patent backing for key drugs Lumigan and Restasis. Article | Follow @CarlyHFierce

> South Korea's Celltrion won regulatory approval in its home country for Herzuma, its biosimilar version of Roche's ($RHHBY) original breast cancer blockbuster, Herceptin. Report

> Hungary became the latest EU country to approve AirFluSal Forspiro, a generic version of GlaxoSmithKline's ($GSK) blockbuster lung drug Advair made by Novartis' ($NVS) generics unit, Sandoz. Report

> Amarin ($AMRN) said the FDA delayed a decision on a large, late-stage trial of its Vascepa blood-lipid drug; it's the latest obstacle for Amarin in its quest to win approval to market the drug to a broader group of patients. Release |  Report

> Novo Nordisk ($NVO) made Fortune's latest list of the 100 best companies to work for, ranked 72nd. Release

> Amgen ($AMGN) teamed up with the gene-sequencing specialist Illumina ($ILMN) to develop a diagnostic test to identify patients for its targeted colon cancer drug Vectibix. Report

> Allergan ($AGN) CEO David Pyott says he's not interested in buying an Irish company to lower his company's corporate taxes. Report

Medical Device News

@FierceMedDev: Thermo nabs Chinese approval of $13.6B Life Tech merger. More | Follow @FierceMedDev

@MarkHFierce: Even N.Y. Sen. Chuck Schumer spilled the beans about Carlyle Group's bid for J&J's Ortho Clinical diagnostics arm. Story | Follow @MarkHFierce

@MichaelGFierce: Cynapsus' sublingual strip for severe Parkinson's reduces side effects in a study. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Integra finalizes $235M deal for Covidien's surgical products line. News | Follow @EmilyWFierce

@GalenMoore: Bio-Path Holdings is raising $10M for its cancer drug delivery tech. Release | Follow @GalenMoore

> Medtronic must pay Edwards at least $394M in heart valve patent trial defeat. Report

> Illumina will concoct a companion Dx for an Amgen colon cancer drug. Item

> Fallout from Orthofix's Medicare kickback scandal takes down a VA podiatrist. More

Biotech News

@FierceBiotech: Merck clears an FDA panel with its clot-fighting vorapaxar. Story | Follow @FierceBiotech

@JohnCFierce: ICYMI: Roche's dealmakers at pRED will continue their global shopping spree in 2014. More | Follow @JohnCFierce

@DamianFierce: Sarepta still climbing on renewed hopes for eteplirsen. Article | Follow @DamianFierce

@EmilyMFierce: Per the FDA's new stance on antibacterials, here's a list of household products containing triclosan. | Follow @EmilyMFierce

> Amarin endures another FDA delay as Vascepa languishes. More

> J&J shipping out diagnostics biz for $4.2B. Report

> Gentium shareholders cry foul on $1B Jazz deal. News

Pharma Manufacturing News

> Merck recalls all lots of Liptruzet shipped since its May debut. Story

> Former Fresenius employee says he was fired for raising red flags. Article

> Premier supports new FDA compounder oversight plan. Report

> FDA assigns an agent to Europol in its fight against fakes. More

> Sources: Ranbaxy asks the FDA to let it make generic Diovan in U.S. News

> Actavis selling China assets as it exits that country. Item

Vaccines News

> CDC, FDA studies link Merck and GSK rotavirus vaccines to bowel blockages. Story

> BIO and Sanofi are pushing the FDA to tweak its drug shortage rule for vaccines. Story

> A Dendreon consultant has raised $8M for a cancer vaccine startup. Story

> Buzz: Merck and Novartis trying to iron out details of their business unit swap. Story

> AC Immune begins first trial of a tau-targeting Alzheimer's vaccine. Story

> Astellas and Takeda continue to advance vaccine strategies. Item

And Finally... Rotavirus vaccines from Merck ($MRK) and GlaxoSmithKline ($GSK) may carry a small risk of a type of bowel obstruction, but not enough to change recommendations for their use. Report

Suggested Articles

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.